Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Review ArticleProceedings of the XI International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy, 11-14 October 2012, Verona, ItalyR

Membrane Transporters as Mediators of Cisplatin Side-effects

GIULIANO CIARIMBOLI
Anticancer Research January 2014, 34 (1) 547-550;
GIULIANO CIARIMBOLI
Experimental Nephrology, Department of Internal Medicine D, and Interdisciplinary Center for Clinical Research (IZKF), University Hospital Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gciari@uni-muenster.de
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The clinical use of the efficient chemotherapeutic drug cisplatin is limited by its specific severe organ toxicities such as nephro-, oto-, and also peripheral neurotoxicity. Membrane transporters such as the copper transporter-1 (Ctr1), the copper transporter-2 (Ctr2), the P-type copper-transporting ATPases ATP7A and ATP7B, the organic cation transporter-2 (OCT2), and the multidrug extrusion transporter-1 (MATE1) mediate cellular transport of cisplatin. Since OCT2 is specifically expressed in the kidneys, its role as possible target of specific organ protection against undesired cisplatin toxicity is under investigation. We could show that OCT2 is also expressed in the cochlea in hair cells and in cells of the stria vascularis and also in dorsal root ganglia of mice. Moreover, we could show in a mouse model of cisplatin acute toxicities that the expression of OCT is critical for the development of ototoxicity, peripheral neurotoxicity and nephrotoxicity. Competition of cisplatin transport by the OCT2 substrate cimetidine was able to suppress ototoxicity, and reduce nephrotoxicity. Only few human tumors express OCT2, its expression being apparently down-regulated by epigenetic modifications, suggesting that a protective therapy by competition for the transport of cisplatin by OCT2 may be generally feasible without affecting its antitumor potency. There is already some evidence that patients bearing a mutation in OCT2 gene or co-medicated with cimetidine are protected against cisplatin nephrotoxicity. In conclusion, OCT2 seems to be an ideal target for the establishment of protective therapies aimed to specifically reduce cisplatin side-effects and increase the quality of life of the patients.

  • Transporters
  • cisplatin
  • toxicities
  • review
  • membrane transporters
  • Ctr2
  • OCT2
  • MATE1

Introduction. Intracellular-acting drugs must cross biological membranes to reach their targets. In the case of lipophilic drugs, the passage through plasma membranes happens largely via passive diffusion at a rate related to their lipophilicity, while in the case of hydrophilic drugs this process is mediated by membrane transporters. Many membrane transporters have a specific tissue and cell distribution: in the morphologically- and functionally-polarized epithelial tissues, for example, transporters are even specifically expressed on the apical or basolateral cell membrane. In this way, a specific drug-transporter interaction can be exploited to target drugs to selected cells and tissues, but of course can also explain specific undesired adverse effects (1). While the pharmacological relevance of transport proteins is well-known because of their role in the development of resistance of tumor cells to chemotherapeutic agents (as for example in the case of P-glycoprotein (2)), their role in the development of specific drug adverse effects has been only in the recent years under critical investigation (1).

Cisplatin is a potent and efficient cytostatic drug, whose clinical use is limited by its severe acute and chronic nephro-, oto- and peripheral neurotoxicity (3). In this work I summarize our results presented at the the XIth International Symposium on Platin Coordination Compound in Cancer held in Verona (Italy) on the role of membrane transporters in mediating specific cisplatin uptake and toxicities and the thereby possible implications for protective therapies.

Cisplatin toxicities. Cisplatin treatment, even though effective against tumors, has severe side-effects such as nephrotoxicity, which is often dose-limiting, ototoxicity, and peripheral neurotoxicity. Clinical signs of acute and/or chronic nephrotoxicity are a decrease in renal plasma flow (4) and in glomerular filtration rate (5), an increase in serum creatinine, and reduction of serum magnesium and potassium levels (6). Even though nephrotoxicity can be controlled by diuretics and pre-hydration of patients, the prevalence of cisplatin nephrotoxicity is still high, occurring in about one-third of patients undergoing cisplatin treatment (6). Studies in experimental animals showed that the kidney accumulates more cisplatin than other organs (7), and that the proximal tubules are the renal structure specifically damaged by cisplatin (8). Ototoxicity, an untypical side-effect for a chemotherapeutic drug, is caused by a damage first occurring at the cochlea base, where high-frequency sounds are processed, which, with increasing cumulative dose, proceeds towards the apex, affecting also hearing at lower frequencies (9). Cisplatin treatment causes hearing loss, possibly leading to deafness, which is still an unresolved clinical problem of dramatic importance in infants and younger children, where ototoxicity can lead to a delayed language development which in turn might have devastating consequences for a young child's social and educational development (10). Most patients treated with cisplatin develop a symptomatic and clinically-detectable sensory neuropathy, caused by its preferential uptake in the dorsal root ganglia (DRG), which produces a dose-related large fiber sensory neuropathy (11, 12).

Cisplatin transporters. Several different transporters seem to be involved in the cellular transport of cisplatin: the copper transporter-1 (Ctr1) (13), the copper transporter-2 (Ctr2) (14), the P-type copper-transporting ATPases ATP7A and ATP7B (15), the organic cation transporter-2 (OCT2) (16, 17), and the multidrug and toxin extrusion transporter 1 (MATE1) (18, 19). While Ctr1, Ctr2, ATP7A and ATP7B are ubiquitary expressed, OCTs and MATE1 are highly expressed in secretory organs, such as the liver and the kidneys, and for this reason, are of special interest as mediators of specific organ toxicities. Focussing on OCTs, these transporters have a species- and subtype-specific organ expression: human OCT2 (hOCT2) is specifically expressed in the basolateral membrane of renal proximal tubule cells, while human hepatocytes express mainly hOCT1 in their sinusoidal membrane (20). For the right interpretation of translational studies, it is important to mention that in rodents, both OCT1 and OCT2 show a high renal expression in the basolateral membrane of proximal tubule cells, with higher OCT2 expression in male animals (21,22).

We furnished the first direct in vitro evidences for the transport of cisplatin by hOCT2 showing that it inhibits the uptake of the fluorescent organic cation 4-(4-(dimethylamino) styryl)-N-methylpyridinium (ASP+) by hOCT2 stably transfected in human embryonic kidney (HEK) cells. The expression of hOCT2 was also linked to a higher cisplatin accumulation compared to wild-type HEK cells (16). These findings were confirmed by other groups studying cisplatin uptake by rat OCT2 (23) and by hOCT2 (24). We could also showed that cisplatin competed with ASP+ basolateral transport in freshly-isolated human proximal tubules (where hOCT2 is expressed), whereas it did not influence ASP+ transport in human hepatocytes (where hOCT1 is expressed) (16). Moreover, competition of hOCT2 transport by the OCT substrate cimetidine effectively suppressed cisplatin cellular toxicity in vitro (16). The introduction of mice, where the genes for OCT1 and OCT2 were genetically deleted (OCT1 and 2 knock-out -ko- mice) (25) allowed us (17) and others (26) to study the importance of these transporters for the development of acute cisplatin toxicities in vivo. Compared with wild-type mice, OCT1 and 2 ko mice developed a much milder nephrotoxicity under acute treatment with cisplatin (17). Interestingly, these mice were also protected against cisplatin induced ototoxicity (17). Because of this finding, we investigated the expression of OCT2 in the mouse cochlea and were able to show its expression in hair cells and in the cells of the stria vascularis, structures sensitive to cisplatin damage. Recently, performing laser-ablation mass spectrometry experiments in wildtype mice acutely treated with cisplatin, we were able to show a high accumulation of cisplatin in the kidney cortex and also in the stria vascularis of the cochlea, areas where OCT are specifically expressed (27). Interestingly, treatment of the wildtype animals with cisplatin together with cimetidine, a competitor for the transport by OCT, eliminated or lowered the ototoxic and nephrotoxic effects of cisplatin, respectively (17). The reason for incomplete protection from cisplatin nephrotoxicity by cimetidine may reside in the vectorial nature of cisplatin transport in renal proximal tubules: cimetidine inhibits with higher affinity the apical expressed MATE1 (28), probably an efflux transporter for cisplatin, in this way probably reducing its renoprotective effect. A study in rats showed that such a protective strategy did not interfere with the anti-tumoral activity of cisplatin (29). Interestingly, OCT2 has been demonstrated to be expressed in DRG within the nervous system (30). Genetic or pharmacological knockout of OCT2 protected mice from hypersensitivity to cold or mechanical-induced allodynia induced by oxaliplatin treatment (30). Even though the idea of a specific protective therapy aimed to reduce cisplatin toxicities by competing its uptake by OCT is very attractive, it is important not to compromise its uptake in tumor cells, the target of cisplatin therapy. Investigating the transporter expression in several different tumor derived cell lines, we found a strong expression of Ctr1 but no or only a very low expression of OCT, at least at the mRNA level (17). However, colorectal tumor samples expressed hOCT2 (31), while a reduced expression of OCT1, OCT2, and OCT3 due to epigenetic modifications such as DNA methylation was observed both in animal models and in prostate and liver tumor patients (32-34). There are few studies in patients suggesting a protective effect of cimetidine against and an important role for hOCT2 for the development of cisplatin nephrotoxicity. One study suggested already 1987 an efficient nephroprotection by cimetidine in patients treated with cisplatin, without compromising the success of tumor therapy (35). Another study showed that patients bearing a mutation in hOCT2, which decreases transport function, were protected against cisplatin nephrotoxicity (26). A recent study showed that both co-medication with cimetidine and genetic polymorphism of hOCT2 protected patients against cisplatin nephrotoxicity (36).

Collectively, these results indicate the critical importance of OCT2 in the handling of cisplatin in the kidney, in the inner ear and possibly also in DRG and provide a rationale for the development of new targeted approaches to mitigate these debilitating side effects of cisplatin chemotherapy.

Acknowledgements

The work of the Author on this topic is supported by the Interdisciplinary Center for Clinical Research (IZKF) Münster (Grant Cia2/013/13) and by the Deutsche Krebshilfe (grant 108539).

  • Received November 6, 2013.
  • Revision received December 6, 2013.
  • Accepted December 9, 2013.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Ciarimboli G
    : Role of organic cation transporters in drug-induced toxicity. Expert Opin Drug Metab Toxicol 7: 159-174, 2011.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Zhou SF
    : Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832, 2008.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Rabik CA,
    2. Dolan ME
    : Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Fillastre JP,
    2. Raguenez-Viotte G
    : Cisplatin nephrotoxicity. Toxicol Lett 46: 163-175, 1989.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Daugaard G
    : Cisplatin nephrotoxicity: experimental and clinical studies. Dan Med Bull 37: 1-12, 1990.
    OpenUrlPubMed
  6. ↵
    1. Pabla N,
    2. Dong Z
    : Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Litterst CL,
    2. Gram TE,
    3. Dedrick RL,
    4. LeRoy AF,
    5. Guarino AM
    : Distribution and disposition of platinum following intravenous administration of cis-diamminedichloroplatinum(II) (NSC 119875) to dogs. Cancer Res 36: 2340-2344, 1976.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Dobyan DC,
    2. Levi J,
    3. Jacobs C,
    4. Kosek J,
    5. Weiner MW
    : Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213: 551-556, 1980.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Rybak LP
    : Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15: 364-369, 2007.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Skinner R
    : Best practice in assessing ototoxicity in children with cancer. Europ J Cancer 40: 2352-2354, 2004.
    OpenUrlPubMed
  11. ↵
    1. Albers JW,
    2. Chaudhry V,
    3. Cavaletti G,
    4. Donehower RC
    : Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev CD005228, 2011.
  12. ↵
    1. Meijer C,
    2. de Vries EG,
    3. Marmiroli P,
    4. Tredici G,
    5. Frattola L,
    6. Cavaletti G
    : Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology 20: 883-887, 1999.
    OpenUrlPubMed
  13. ↵
    1. Ishida S,
    2. Lee J,
    3. Thiele DJ,
    4. Herskowitz I
    : Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-14302, 2002.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Blair BG,
    2. Larson CA,
    3. Safaei R,
    4. Howell SB
    : Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res 15: 4312-4321, 2009.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Samimi G,
    2. Katano K,
    3. Holzer AK,
    4. Safaei R,
    5. Howell SB
    : Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66: 25-32, 2004.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Ciarimboli G,
    2. Ludwig T,
    3. Lang D,
    4. Pavenstädt H,
    5. Koepsell H,
    6. Piechota HJ,
    7. Haier J,
    8. Jaehde U,
    9. Zisowsky J,
    10. Schlatter E
    : Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 167: 1477-1484, 2005.
    OpenUrlPubMed
  17. ↵
    1. Ciarimboli G,
    2. Deuster D,
    3. Knief A,
    4. Sperling M,
    5. Holtkamp M,
    6. Edemir B,
    7. Pavenstädt H,
    8. Lanvers-Kaminsky C,
    9. Am Zehnhoff-Dinnesen A,
    10. Schinkel AH,
    11. Koepsell H,
    12. Jurgens H,
    13. Schlatter E
    : Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 176: 1169-1180, 2010.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Yonezawa A,
    2. Masuda S,
    3. Yokoo S,
    4. Katsura T,
    5. Inui K
    : Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319: 879-886, 2006.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Nakamura T,
    2. Yonezawa A,
    3. Hashimoto S,
    4. Katsura T,
    5. Inui KI
    : Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 80: 1762-1767, 2010.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Ciarimboli G
    : Organic cation transporters. Xenobiotica 38: 936-971, 2008.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Urakami Y,
    2. Nakamura N,
    3. Takahashi K,
    4. Okuda M,
    5. Saito H,
    6. Hashimoto Y,
    7. Inui K
    : Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett 461: 339-342, 1999.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Meetam P,
    2. Srimaroeng C,
    3. Soodvilai S,
    4. Chatsudthipong V
    : Regulatory role of testosterone in organic cation transport: in vivo and in vitro studies. Biol Pharm Bull 32: 982-987, 2009.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Yonezawa A,
    2. Masuda S,
    3. Nishihara K,
    4. Yano I,
    5. Katsura T,
    6. Inui K
    : Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol 70: 1823-1831, 2005.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Filipski KK,
    2. Loos WJ,
    3. Verweij J,
    4. Sparreboom A
    : Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14: 3875-3880, 2008.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Jonker JW,
    2. Wagenaar E,
    3. Van Eijl S,
    4. Schinkel AH
    : Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23: 7902-7908, 2003.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Filipski KK,
    2. Mathijssen RH,
    3. Mikkelsen TS,
    4. Schinkel AH,
    5. Sparreboom A
    : Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86: 396-402, 2009.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Reifschneider O,
    2. Wehe CA,
    3. Raj I,
    4. Ehmcke J,
    5. Ciarimboli G,
    6. Sperling M,
    7. Karst U
    : Quantitative bioimaging of platinum in polymer embedded mouse organs using laser ablation ICP-MS. Metallomics 5: 1440-1447, 2013.
    OpenUrlPubMed
  28. ↵
    1. Ito S,
    2. Kusuhara H,
    3. Yokochi M,
    4. Toyoshima J,
    5. Inoue K,
    6. Yuasa H,
    7. Sugiyama Y
    : Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 340: 393-403, 2012.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Katsuda H,
    2. Yamashita M,
    3. Katsura H,
    4. Yu J,
    5. Waki Y,
    6. Nagata N,
    7. Sai Y,
    8. Miyamoto K
    : Protecting Cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol Pharm Bull 33: 1867-1871, 2010.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Sprowl JA,
    2. Ciarimboli G,
    3. Lancaster CS,
    4. Giovinazzo H,
    5. Gibson AA,
    6. Du G,
    7. Janke LJ,
    8. Cavaletti G,
    9. Shields AF,
    10. Sparreboom A
    : Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci USA 110: 11199-11204, 2013.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Zhang S,
    2. Lovejoy KS,
    3. Shima JE,
    4. Lagpacan LL,
    5. Shu Y,
    6. Lapuk A,
    7. Chen Y,
    8. Komori T,
    9. Gray JW,
    10. Chen X,
    11. Lippard SJ,
    12. Giacomini KM
    : Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66: 8847-8857, 2006.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Yang J,
    2. Kalogerou M,
    3. Gallacher J,
    4. Sampson JR,
    5. Shen MH
    : Renal tumours in a Tsc1+/− mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. Eur J Cancer 49: 1479-1490, 2013.
    OpenUrlPubMed
    1. Schaeffeler E,
    2. Hellerbrand C,
    3. Nies AT,
    4. Winter S,
    5. Kruck S,
    6. Hofmann U,
    7. van der Kuip H,
    8. Zanger UM,
    9. Koepsell H,
    10. Schwab M
    : DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 3: 82, 2011.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Chen L,
    2. Hong C,
    3. Chen EC,
    4. Yee SW,
    5. Xu L,
    6. Almof EU,
    7. Wen C,
    8. Fujii K,
    9. Johns SJ,
    10. Stryke D,
    11. Ferrin TE,
    12. Simko J,
    13. Chen X,
    14. Costello JF,
    15. Giacomini KM
    : Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J 13: 110-120, 2013.
    OpenUrlPubMed
  34. ↵
    1. Sleijfer DT,
    2. Offerman JJ,
    3. Mulder NH,
    4. Verweij M,
    5. van der Hem GK,
    6. Schraffordt Koops HS,
    7. Meijer S
    : The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60: 2823-2828, 1987.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Zhang J,
    2. Zhou W
    : Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol 50: 2289-2293, 2012.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (1)
Anticancer Research
Vol. 34, Issue 1
January 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Membrane Transporters as Mediators of Cisplatin Side-effects
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Membrane Transporters as Mediators of Cisplatin Side-effects
GIULIANO CIARIMBOLI
Anticancer Research Jan 2014, 34 (1) 547-550;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Membrane Transporters as Mediators of Cisplatin Side-effects
GIULIANO CIARIMBOLI
Anticancer Research Jan 2014, 34 (1) 547-550;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Acknowledgements
    • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin
  • Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery
  • Google Scholar

More in this TOC Section

  • Biography of Professor Barnett Rosenberg: A Tribute to His Life and His Achievements
  • Antidepressants and Platinum Drugs
  • Platinum Drugs and DNA Repair Mechanisms in Lung Cancer
Show more Proceedings of the XI International Symposium of Platinum Coordination Compounds in Cancer Chemotherapy, 11-14 October 2012, Verona, Italy

Similar Articles

Keywords

  • Transporters
  • Cisplatin
  • toxicities
  • review
  • membrane transporters
  • Ctr2
  • OCT2
  • MATE1
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire